Physician profile
Wallace Nozile
NPI 1093101107
$213,162.38
in general payments reported to CMS, 2019-2025
23 companies · $178K in 2025
The $178K reported for 2025 was more than what 99% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $139 · 2021: $924 · 2022: $1,380 · 2023: $1,133 · 2024: $31K · 2025: $178K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120K · Travel and Lodging: $40K · Food and Beverage: $27K · Consulting Fee: $23K · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,996.50 |
| Travel and Lodging | $40,008.45 |
| Food and Beverage | $26,935.80 |
| Consulting Fee | $23,437.50 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $146,460.73 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $47,597.87 | 2023-2025 | Zoryve |
| Abbvie INC. | $13,311.78 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,288.25 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $964.56 | 2020-2025 | |
| Lilly USA, LLC | $501.53 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $490.10 | 2019-2025 | Dupixent |
| Ucb, INC. | $393.24 | 2024-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $290.52 | 2024-2025 | Tremfya |
| Incyte Corporation | $274.81 | 2022-2025 | Opzelura |
| Pfizer INC. | $257.75 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $249.09 | 2021-2025 | Blu-U, Odomzo |
| Novartis Pharmaceuticals Corporation | $209.65 | 2019-2025 | |
| Dermavant Sciences, INC. | $172.52 | 2022-2024 | Vtama |
| Allergan, INC. | $136.36 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $131.19 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $114.35 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $81.32 | 2024 | Sotyktu |
| Leo Pharma INC. | $78.26 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.31 | 2022-2025 | Spevigo |
| Journey Medical Corporation | $42.01 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $31.98 | 2022 | |
| Organon LLC | $15.20 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Nozile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.